Skip to content
drillr.ai
Sign up

QURE

uniQure NV

NASDAQ · Healthcare · Biotechnology · NL

$25.30
+1.32%
Ask drillr

  • Oct 28, 2026, 11:05 UTC

    uniQure N.V. announced that it will report its third-quarter 2026 financial results and host an earnings call on November 4, 2026, at 8:30 a.m. ET.

    Source:

  • Sep 30, 2026, 00:12 UTC

    SueWallSt announced a pending investigation into potential securities law violations by uniQure following a decline in QURE shares after its four-year AMT-130 Huntington's disease data came in smaller than the three-year result.

    Source:

  • Sep 29, 2026, 13:00 UTC

    Uniqure shares plummeted 40% on Tuesday after a disappointing four-year update for its experimental gene therapy in Huntington's disease patients.

    Source:

  • Sep 29, 2026, 11:12 UTC

    uniQure announced additional data from ongoing Phase I/II studies of ifezuntirgene inilparvovec (AMT-130) in Huntington's disease, showing continued slowing of disease progression in 12 high-dose patients at 48 months.

    Source:

  • Sep 2, 2026, 12:23 UTC

    uniQure submitted a Biologics License Application to the U.S. FDA for its Huntington's disease gene therapy after the FDA reversed its earlier position on the drug.

    Source:

  • Jul 29, 2026, 13:31 UTC

    uniQure reported a quarterly loss of $1.22 per share for Q2 2026, missing the Zacks Consensus Estimate of a loss of $0.81 per share and compared to a loss of $0.69 per share a year ago.

    Source:

  • Jun 24, 2026, 00:00 UTC

    uniQure N.V. signed an underwriting agreement for an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, with underwriters fully exercising an option for additional shares, expected to close on June 25, 2026.

    Source:

  • Jun 22, 2026, 15:31 UTC

    uniQure announces initial data from its gene therapy AMT-260 for temporal lobe epilepsy, showing seizure reductions in three patients.

    Source:

  • Jun 22, 2026, 12:56 UTC

    UniQure was cleared to submit an application for a Huntington's disease gene therapy that the agency had previously spurned.

    Source:

  • Jun 19, 2026, 19:20 UTC

    The FDA stated that uniQure's AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.

    Source:

  • Jun 19, 2026, 11:05 UTC

    uniQure announced preliminary six-month follow-up data from the first cohort of its Phase I/IIa clinical trial of AMT-260 for refractory mesial temporal lobe epilepsy at the Epilepsy Foundation Pipeline Conference.

  • Jun 18, 2026, 00:08 UTC

    The FDA accepted data analysis from UniQure's AMT-130 phase 1 clinical study, allowing submission of a biologics license application.

    Source: